lemzoparlimab + carfilzomib + dexamethasone

**Lemzoparlimab + carfilzomib + dexamethasone** is a three-drug investigational combination regimen for the treatment of multiple myeloma, particularly in the relapsed and/or refractory setting. Lemzoparlimab is a monoclonal antibody targeting CD47, designed to block the “don’t eat me” signal on tumor cells and enhance phagocytosis by macrophages (immunotherapy). Carfilzomib is a small molecule, irreversible proteasome inhibitor that induces apoptosis in multiple myeloma cells by blocking protein degradation and causing buildup of toxic proteins. Dexamethasone is a synthetic glucocorticoid corticosteroid that modulates inflammation and immune response and is commonly used in multiple myeloma regimens to enhance anti-myeloma activity and reduce side effects such as infusion reactions. This triple combination is in clinical development for relapsed and/or refractory multiple myeloma, and leverages immunomodulatory, targeted, and anti-inflammatory mechanisms.

Other names

lemzoparlimabTJ202TJ-202TJ 202carfilzomibPR-171PR171PR 171Kyprolisdexamethasone